HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib.

Abstract
A drawback of extensive coxib use for antitumor purposes is the risk of life-threatening side effects that are thought to be a class effect and probably due to the resulting imbalance of eicosanoid levels. 2,5-Dimethyl-celecoxib (DMC) is a close structural analogue of the selective cyclooxygenase-2 inhibitor celecoxib that lacks cyclooxygenase-2-inhibitory function but that nonetheless is able to potently mimic the antitumor effects of celecoxib in vitro and in vivo. To further establish the potential usefulness of DMC as an anticancer agent, we compared DMC and various coxibs and nonsteroidal anti-inflammatory drugs with regard to their ability to stimulate the endoplasmic reticulum (ER) stress response (ESR) and subsequent apoptotic cell death. We show that DMC increases intracellular free calcium levels and potently triggers the ESR in various tumor cell lines, as indicated by transient inhibition of protein synthesis, activation of ER stress-associated proteins GRP78/BiP, CHOP/GADD153, and caspase-4, and subsequent tumor cell death. Small interfering RNA-mediated knockdown of the protective chaperone GRP78 further sensitizes tumor cells to killing by DMC, whereas inhibition of caspase-4 prevents drug-induced apoptosis. In comparison, celecoxib less potently replicates these effects of DMC, whereas none of the other tested coxibs (rofecoxib and valdecoxib) or traditional nonsteroidal anti-inflammatory drugs (flurbiprofen, indomethacin, and sulindac) trigger the ESR or cause apoptosis at comparable concentrations. The effects of DMC are not restricted to in vitro conditions, as this drug also generates ER stress in xenografted tumor cells in vivo, concomitant with increased apoptosis and reduced tumor growth. We propose that it might be worthwhile to further evaluate the potential of DMC as a non-coxib alternative to celecoxib for anticancer purposes.
AuthorsPeter Pyrko, Adel Kardosh, Yen-Ting Liu, Nathaniel Soriano, Wenyong Xiong, Robert H Chow, Jasim Uddin, Nicos A Petasis, Austin K Mircheff, Robert A Farley, Stan G Louie, Thomas C Chen, Axel H Schönthal
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 6 Issue 4 Pg. 1262-75 (Apr 2007) ISSN: 1535-7163 [Print] United States
PMID17431104 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 2,5-dimethylcelecoxib
  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Endoplasmic Reticulum Chaperone BiP
  • HSPA5 protein, human
  • Heat-Shock Proteins
  • Hspa5 protein, mouse
  • Molecular Chaperones
  • Pyrazoles
  • Sulfonamides
  • Transcription Factor CHOP
  • Thapsigargin
  • CASP4 protein, human
  • Caspases, Initiator
  • Celecoxib
  • Calcium
Topics
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal (pharmacology)
  • Calcium (metabolism)
  • Caspases, Initiator (metabolism)
  • Celecoxib
  • Cell Death (drug effects)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Cyclooxygenase 2 Inhibitors (pharmacology)
  • Cytoplasm (drug effects)
  • Endoplasmic Reticulum (drug effects, pathology)
  • Endoplasmic Reticulum Chaperone BiP
  • Heat-Shock Proteins (metabolism)
  • Humans
  • Mice
  • Mice, Nude
  • Molecular Chaperones (metabolism)
  • Protein Biosynthesis (drug effects)
  • Pyrazoles (blood, pharmacology)
  • Sulfonamides (blood, pharmacology)
  • Thapsigargin (pharmacology)
  • Transcription Factor CHOP (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: